Can Direct Oral Anticoagulants Be Used for Stroke Prevention Among Patients with Valvular Atrial Fibrillation?

被引:0
作者
Sarah L. Anderson
Joel C. Marrs
机构
[1] University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences,Department of Clinical Pharmacy
来源
Current Cardiology Reports | 2019年 / 21卷
关键词
Direct oral anticoagulant; Valvular atrial fibrillation; Atrial fibrillation; Anticoagulation;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 276 条
[1]  
Benjamin EJ(2019)Heart disease and stroke statistics – 2019 update: a report from the American Heart Association Circulation 139 e56-e528
[2]  
Muntner P(2004)Lifetime risk for development of atrial fibrillation: the Framingham Heart Study Circulation 110 1042-1046
[3]  
Alonso A(1982)Epidemiologic features of chronic atrial fibrillation: the Framingham Study N Engl J Med 306 1018-1022
[4]  
Bittencourt MS(1998)Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 946-952
[5]  
Callaway CW(2001)Epidemiology and natural history of atrial fibrillation: clinical implications J Am Coll Cardiol 37 371-2379
[6]  
Carson AP(2014)Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning Circulation 129 2371-e93
[7]  
Chamberlain AM(2019)2019 AHA/ACC/HRS focused update of the 2015 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society Heart Rhythm 16 e66-3335
[8]  
Chang AR(2014)What is “valvular” atrial fibrillation? A reappraisal Eur Heart J 35 3328-992
[9]  
Cheng S(2011)Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 981-1151
[10]  
Das SR(2009)Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139-2104